Merck & Company (MRK) 60.32 $MRK
Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers
at The Street - 1 hr 25 mins ago
Shire has cash for what could be a $5 billion deal, but treatment base is limited.
CBST: 100.80 (+0.12), SHPG: 207.14 (+1.09), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), NPSP: 41.05 (+2.92), ABBV: 64.33 (-0.32), HSP: 60.63 (-0.33)
Merck Set to Possibly Pullback After Yesterday's Rally of 3.93%
Comtex SmarTrend(R) - 2 hrs 18 mins ago
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.25 to a high of $60.50. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $58.48 on volume of 24.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 60.32 (+2.28)
Look for Shares of Merck to Potentially Pullback after Yesterday's 3.93% Rise
Comtex SmarTrend(R) - 2 hrs 19 mins ago
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.25 to a high of $60.50. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $58.48 on volume of 24.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 60.32 (+2.28)
Dow Jones (DJIA) Today: Merck (MRK) Higher
at The Street - Tue Jan 06, 1:00PM CST
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 61-cent gain (+1.1%) bringing the stock to $58.65.
MRK: 60.32 (+2.28)
Next Resistance Level for Merck (MRK) is $58.94
Comtex SmarTrend(R) - Tue Jan 06, 12:23PM CST
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $58.03 today and have reached the first resistance level of $58.49. Investors may be interested in a cross of the next upside pivot targets of $58.94 and $59.85.
MRK: 60.32 (+2.28)
Dow Correction: Why This Popular Move Might Not Save You
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jan 06, 10:17AM CST
Source: Wikimedia Commons , Jean-Pierre Lavoie. Monday's 331-point plunge in the Dow Jones Industrials set investors on edge, raising fears that the 6-year-old bull market might finally be drawing to a close. In response, many nervous investors...
KO: 42.46 (+0.32), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), MCD: 92.40 (+0.17)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.99 (-0.68), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), OPK: 9.91 (-0.15), MRK: 60.32 (+2.28), IBB: 300.81 (-5.04), AGIO: 111.43 (+2.56), TEVA: 54.93 (-0.16), CELG: 110.51 (-1.42)
HMR Weight Management Services Named No. 2 Best Weight-Loss Diet in U.S. News & World Report's Best Diets of 2015
PR Newswire - Tue Jan 06, 8:15AM CST
HMR Weight Management Services (HMR), a subsidiary of Merck, announced today that it has been named the No. 2 Best Weight-Loss Diet in U.S. News & World Reports' Best Diets of 2015 rankings. The ranking was based on both short and long-term weight-loss ratings.
MRK: 60.32 (+2.28)
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), MRK: 60.32 (+2.28), GM: 34.85 (+0.52), STXS: 1.70 (-0.18)
Dow Dividend Dogs: Yahoo Finds 2.83% Edge For 5 Lowest Price High Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 6:46AM CST
KO: 42.46 (+0.32), T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47)
Theralase Anti-Cancer Technology Picks Up Steam
ACCESSWIRE - Tue Jan 06, 6:00AM CST
WHITEFISH, MT / ACCESSWIRE / January 6, 2015 / There are many different approaches to treating cancer, ranging from Roche Holding Ltd.'s (OTC: RHHBY) monoclonal antibody Perjeta to Merck & Co. Inc.'s (NYSE: MRK) immunotherapy Keytruda. While both of these drugs have made great strides over the past couple years, some companies are looking beyond the standard ways of combatting cancer and pioneering entirely new approaches to treatment.
MRK: 60.32 (+2.28), TLT.VN: 0.450 (-0.050)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 60.32 (+2.28), GSK: 41.68 (-0.23), IMUC: 0.72 (-0.02), HPTX: 23.34 (-1.00)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 158.65 (-1.71), NWBO: 5.41 (unch), MRK: 60.32 (+2.28), IMUC: 0.72 (-0.02)
Global Non Small Cell Lung Cancer Market & Pipeline Insight 2015 - 268 Drugs with 99 in Phase-II Trials and 30 Marketed NSCLC Drugs
M2 - Tue Jan 06, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x4pv5/global_non_small) has announced the addition of the "Global Non Small Cell Lung Cancer Market & Pipeline Insight" report to their offering. Advances in monoclonal antibody (mAbs) development technology are expected to evolve further in coming years due to which they may become major NSCLC therapeutic in market. Their potency is expected to increase along with minimum side effects and increase in specificity. The marketing potential of mAbs is expected to increase as they have proven track record and widely accepted by oncologists and patients. The developers of mAbs would consider that the simultaneous evolution of targeted and enzyme inhibitor therapies coupled with other therapies are in developing stages which will give them severe competition after some time. Their market share may get eroded by new NSCLC therapeutics which is likely to provide better pharmacological effect at competitive pricing. Large clinical development pipeline for NSCLC therapeutics is expected to grow at tremendous rates in coming years. Pharmaceutical companies are investing significant amount of funds in clinical trials which may help large number of patients. But these therapeutics have prove their worth in clinical trials along with statistically significant data on safety and efficacy will be required. They will also take few years in passing regulatory hurdles and marketing authorization before providing medical care to NSCLC patients. Global Non Small Cell Lung Cancer Market & Pipeline Insight Report Highlights: - NSCLC Therapy Market Overview - Mechanism of NSCLC Therapeutics - NSCLC Therapy Market Dynamics: Drivers, Challenges & Future Prospects) - NSCLC Drug Pipeline by Phase, Company & Country - NSCLC Clinical Pipeline: 268 Drugs - Majority of NSCLC Drugs in Phase-II Trials: 99 - Marketed NSCLC Drugs: 30 Key Topics Covered: 1. Introduction to Non Small Cell Lung Cancer 2. Mechanism of Non Small Cell Lung Cancer Therapeutics 3. Non Small Cell Lung Cancer Therapy Market Overview 4. Non Small Cell Lung Cancer Therapy Market Dynamics 5. Non Small Cell Lung Cancer Therapy Market Future Prospects 6. Non Small Cell Lung Cancer Drug Pipeline by Phase, Company & Country 7. Marketed Non Small Cell Lung Cancer Drugs 8. Suspended & Discontinued Non Small Cell Lung Cancer Drug Pipeline 9. Competitive Landscape - AstraZeneca - Biodesix - Chugai Pharmaceutical - Eli Lily - GlaxoSmithKline - Merck - Novartis AG - Pfizer - Roche - Transgene For more information visit http://www.researchandmarkets.com/research/6x..._non_small
MRK: 60.32 (+2.28), GSK: 41.68 (-0.23), NVS: 91.67 (-0.78)
Dow Dividend Dogs: Arbitrage Finds .32% Advantage For 5 Lowest-Priced, High-Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 12:21AM CST
T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01)
A Dozen Dow Dividend Dogs Dance About 9% To 20% Upsides Into January
Fredrik Arnold - at Seeking Alpha - Mon Jan 05, 11:43PM CST
KO: 42.46 (+0.32), MMM: 158.65 (-1.71), GE: 24.07 (-0.53), UNH: 98.92 (-0.20), PFE: 31.42 (+0.26), XOM: 89.81 (-0.48), BA: 127.53 (-1.52), T: 33.60 (+0.05), JPM: 58.98 (-1.57), MRK: 60.32 (+2.28), DD: 70.89 (-0.83), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), MSFT: 45.65 (-0.68), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01), TRV: 103.24 (-0.93)
Shingles Virus May Cause Deafness; CBCD Examines the Medical Evidence
PRWeb - Mon Jan 05, 11:06PM CST
"Infected with the varicella zoster virus (the virus that causes chickenpox and shingles)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
MRK: 60.32 (+2.28)
Brutal Day for Stocks as Crude Oil's Crash Bleeds Energy Sector Dry
at The Street - Mon Jan 05, 4:05PM CST
It was a brutal day on Wall Street as crude oil plunged below $50 a barrel, punishing oil stocks and dealing a hefty blow to the broader stock market.
HK: 1.57 (-0.12), F: 14.62 (-0.14), XOM: 89.81 (-0.48), PDS: 5.18 (-0.29), FCAU: 11.59 (+0.34), SBUX: 79.23 (-0.65), RDS.A: 63.02 (-0.78), GILD: 97.65 (+0.86), MRK: 60.32 (+2.28), GM: 34.85 (+0.52), BP: 35.83 (-0.27), CAT: 86.47 (-0.56), CEMP: 23.15 (-1.40), CVX: 108.03 (-0.05), HMC: 28.82 (-0.16), OAS: 14.76 (-0.67), XLE: 75.12 (-1.12)
Jim Cramer Previews Intel, Microsoft, Home Depot, and More in 2015
at The Street - Mon Jan 05, 3:15PM CST
TheStreet's Jim Cramer previews the Dow in 2015.
MMM: 158.65 (-1.71), GE: 24.07 (-0.53), HD: 100.95 (-0.31), UNH: 98.92 (-0.20), INTC: 35.28 (-0.67), HUM: 139.09 (-0.11), JNJ: 103.28 (-0.51), RDS.B: 64.66 (-0.86), RDS.A: 63.02 (-0.78), GS: 184.53 (-3.81), IBM: 156.07 (-3.44), MRK: 60.32 (+2.28), CAT: 86.47 (-0.56), MSFT: 45.65 (-0.68), CVX: 108.03 (-0.05), ACN: 86.71 (-0.63), CSCO: 27.05 (-0.01)
Stocks Drop 1% In Rising Volume; Visa Falls 1%
at Investor's Business Daily - Mon Jan 05, 9:33AM CST
Stock indexes gapped down at the open and drove further south in early action Monday. The Nasdaq dropped 1% while the S&P 500 and the Dow Jones industrial average shed 1.2% and 1.1%, respectively. Volume was running sharply higher on both major...
V: 257.50 (-1.67), MRK: 60.32 (+2.28), AMGN: 152.90 (-5.09), ILMN: 188.31 (-2.41)
Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers
at The Street - 1 hr 25 mins ago
Shire has cash for what could be a $5 billion deal, but treatment base is limited.
CBST: 100.80 (+0.12), SHPG: 207.14 (+1.09), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), NPSP: 41.05 (+2.92), ABBV: 64.33 (-0.32), HSP: 60.63 (-0.33)
Merck Set to Possibly Pullback After Yesterday's Rally of 3.93%
Comtex SmarTrend(R) - 2 hrs 18 mins ago
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.25 to a high of $60.50. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $58.48 on volume of 24.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 60.32 (+2.28)
Look for Shares of Merck to Potentially Pullback after Yesterday's 3.93% Rise
Comtex SmarTrend(R) - 2 hrs 19 mins ago
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.25 to a high of $60.50. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $58.48 on volume of 24.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 60.32 (+2.28)
Dow Jones (DJIA) Today: Merck (MRK) Higher
at The Street - Tue Jan 06, 1:00PM CST
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 61-cent gain (+1.1%) bringing the stock to $58.65.
MRK: 60.32 (+2.28)
Next Resistance Level for Merck (MRK) is $58.94
Comtex SmarTrend(R) - Tue Jan 06, 12:23PM CST
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $58.03 today and have reached the first resistance level of $58.49. Investors may be interested in a cross of the next upside pivot targets of $58.94 and $59.85.
MRK: 60.32 (+2.28)
Dow Correction: Why This Popular Move Might Not Save You
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jan 06, 10:17AM CST
Source: Wikimedia Commons , Jean-Pierre Lavoie. Monday's 331-point plunge in the Dow Jones Industrials set investors on edge, raising fears that the 6-year-old bull market might finally be drawing to a close. In response, many nervous investors...
KO: 42.46 (+0.32), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), MCD: 92.40 (+0.17)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.99 (-0.68), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), OPK: 9.91 (-0.15), MRK: 60.32 (+2.28), IBB: 300.81 (-5.04), AGIO: 111.43 (+2.56), TEVA: 54.93 (-0.16), CELG: 110.51 (-1.42)
HMR Weight Management Services Named No. 2 Best Weight-Loss Diet in U.S. News & World Report's Best Diets of 2015
PR Newswire - Tue Jan 06, 8:15AM CST
HMR Weight Management Services (HMR), a subsidiary of Merck, announced today that it has been named the No. 2 Best Weight-Loss Diet in U.S. News & World Reports' Best Diets of 2015 rankings. The ranking was based on both short and long-term weight-loss ratings.
MRK: 60.32 (+2.28)
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), MRK: 60.32 (+2.28), GM: 34.85 (+0.52), STXS: 1.70 (-0.18)
Dow Dividend Dogs: Yahoo Finds 2.83% Edge For 5 Lowest Price High Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 6:46AM CST
KO: 42.46 (+0.32), T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47)
Theralase Anti-Cancer Technology Picks Up Steam
ACCESSWIRE - Tue Jan 06, 6:00AM CST
WHITEFISH, MT / ACCESSWIRE / January 6, 2015 / There are many different approaches to treating cancer, ranging from Roche Holding Ltd.'s (OTC: RHHBY) monoclonal antibody Perjeta to Merck & Co. Inc.'s (NYSE: MRK) immunotherapy Keytruda. While both of these drugs have made great strides over the past couple years, some companies are looking beyond the standard ways of combatting cancer and pioneering entirely new approaches to treatment.
MRK: 60.32 (+2.28), TLT.VN: 0.450 (-0.050)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 60.32 (+2.28), GSK: 41.68 (-0.23), IMUC: 0.72 (-0.02), HPTX: 23.34 (-1.00)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 158.65 (-1.71), NWBO: 5.41 (unch), MRK: 60.32 (+2.28), IMUC: 0.72 (-0.02)
Global Non Small Cell Lung Cancer Market & Pipeline Insight 2015 - 268 Drugs with 99 in Phase-II Trials and 30 Marketed NSCLC Drugs
M2 - Tue Jan 06, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x4pv5/global_non_small) has announced the addition of the "Global Non Small Cell Lung Cancer Market & Pipeline Insight" report to their offering. Advances in monoclonal antibody (mAbs) development technology are expected to evolve further in coming years due to which they may become major NSCLC therapeutic in market. Their potency is expected to increase along with minimum side effects and increase in specificity. The marketing potential of mAbs is expected to increase as they have proven track record and widely accepted by oncologists and patients. The developers of mAbs would consider that the simultaneous evolution of targeted and enzyme inhibitor therapies coupled with other therapies are in developing stages which will give them severe competition after some time. Their market share may get eroded by new NSCLC therapeutics which is likely to provide better pharmacological effect at competitive pricing. Large clinical development pipeline for NSCLC therapeutics is expected to grow at tremendous rates in coming years. Pharmaceutical companies are investing significant amount of funds in clinical trials which may help large number of patients. But these therapeutics have prove their worth in clinical trials along with statistically significant data on safety and efficacy will be required. They will also take few years in passing regulatory hurdles and marketing authorization before providing medical care to NSCLC patients. Global Non Small Cell Lung Cancer Market & Pipeline Insight Report Highlights: - NSCLC Therapy Market Overview - Mechanism of NSCLC Therapeutics - NSCLC Therapy Market Dynamics: Drivers, Challenges & Future Prospects) - NSCLC Drug Pipeline by Phase, Company & Country - NSCLC Clinical Pipeline: 268 Drugs - Majority of NSCLC Drugs in Phase-II Trials: 99 - Marketed NSCLC Drugs: 30 Key Topics Covered: 1. Introduction to Non Small Cell Lung Cancer 2. Mechanism of Non Small Cell Lung Cancer Therapeutics 3. Non Small Cell Lung Cancer Therapy Market Overview 4. Non Small Cell Lung Cancer Therapy Market Dynamics 5. Non Small Cell Lung Cancer Therapy Market Future Prospects 6. Non Small Cell Lung Cancer Drug Pipeline by Phase, Company & Country 7. Marketed Non Small Cell Lung Cancer Drugs 8. Suspended & Discontinued Non Small Cell Lung Cancer Drug Pipeline 9. Competitive Landscape - AstraZeneca - Biodesix - Chugai Pharmaceutical - Eli Lily - GlaxoSmithKline - Merck - Novartis AG - Pfizer - Roche - Transgene For more information visit http://www.researchandmarkets.com/research/6x..._non_small
MRK: 60.32 (+2.28), GSK: 41.68 (-0.23), NVS: 91.67 (-0.78)
Dow Dividend Dogs: Arbitrage Finds .32% Advantage For 5 Lowest-Priced, High-Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 12:21AM CST
T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01)
A Dozen Dow Dividend Dogs Dance About 9% To 20% Upsides Into January
Fredrik Arnold - at Seeking Alpha - Mon Jan 05, 11:43PM CST
KO: 42.46 (+0.32), MMM: 158.65 (-1.71), GE: 24.07 (-0.53), UNH: 98.92 (-0.20), PFE: 31.42 (+0.26), XOM: 89.81 (-0.48), BA: 127.53 (-1.52), T: 33.60 (+0.05), JPM: 58.98 (-1.57), MRK: 60.32 (+2.28), DD: 70.89 (-0.83), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), MSFT: 45.65 (-0.68), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01), TRV: 103.24 (-0.93)
Shingles Virus May Cause Deafness; CBCD Examines the Medical Evidence
PRWeb - Mon Jan 05, 11:06PM CST
"Infected with the varicella zoster virus (the virus that causes chickenpox and shingles)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
MRK: 60.32 (+2.28)
Brutal Day for Stocks as Crude Oil's Crash Bleeds Energy Sector Dry
at The Street - Mon Jan 05, 4:05PM CST
It was a brutal day on Wall Street as crude oil plunged below $50 a barrel, punishing oil stocks and dealing a hefty blow to the broader stock market.
HK: 1.57 (-0.12), F: 14.62 (-0.14), XOM: 89.81 (-0.48), PDS: 5.18 (-0.29), FCAU: 11.59 (+0.34), SBUX: 79.23 (-0.65), RDS.A: 63.02 (-0.78), GILD: 97.65 (+0.86), MRK: 60.32 (+2.28), GM: 34.85 (+0.52), BP: 35.83 (-0.27), CAT: 86.47 (-0.56), CEMP: 23.15 (-1.40), CVX: 108.03 (-0.05), HMC: 28.82 (-0.16), OAS: 14.76 (-0.67), XLE: 75.12 (-1.12)
Jim Cramer Previews Intel, Microsoft, Home Depot, and More in 2015
at The Street - Mon Jan 05, 3:15PM CST
TheStreet's Jim Cramer previews the Dow in 2015.
MMM: 158.65 (-1.71), GE: 24.07 (-0.53), HD: 100.95 (-0.31), UNH: 98.92 (-0.20), INTC: 35.28 (-0.67), HUM: 139.09 (-0.11), JNJ: 103.28 (-0.51), RDS.B: 64.66 (-0.86), RDS.A: 63.02 (-0.78), GS: 184.53 (-3.81), IBM: 156.07 (-3.44), MRK: 60.32 (+2.28), CAT: 86.47 (-0.56), MSFT: 45.65 (-0.68), CVX: 108.03 (-0.05), ACN: 86.71 (-0.63), CSCO: 27.05 (-0.01)
Stocks Drop 1% In Rising Volume; Visa Falls 1%
at Investor's Business Daily - Mon Jan 05, 9:33AM CST
Stock indexes gapped down at the open and drove further south in early action Monday. The Nasdaq dropped 1% while the S&P 500 and the Dow Jones industrial average shed 1.2% and 1.1%, respectively. Volume was running sharply higher on both major...
V: 257.50 (-1.67), MRK: 60.32 (+2.28), AMGN: 152.90 (-5.09), ILMN: 188.31 (-2.41)
